Novel scientific insights to unlock the full potential of B cell therapeutics

Diversifying your Cancer Immunotherapy Investments with B cell Activation Approaches

Background on Company
  • Novel scientific insights to unlock the full potential of B cell therapeutics 
  • Range of treatment opportunities for cancer immunotherapy and B cell-driven rare diseases
  • Lead program, AT-1965, advancing toward IND and initiation of solid tumor clinical study in 2H2020
  • Positive pre-IND interaction with FDA; alignment on 2020 IND submission and clinical initiation for AT-1965
  • Collaborative team with leadership across all biotech disciplines; premier scientific advisors and leading entrepreneur backers
  • Financing underway to fund AT-1965 clinical initiation and development
 What you will learn from this webinar
  • How a B cell activation approach differs from other cancer immunotherapy approaches
  • How clinical data drives value creation in cancer immunotherapy
  • How AT-1965 is poised to lead the next frontier in cancer immunotherapy
  • How investment in Akamara will diversify your cancer immunotherapy portfolio